Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans

@article{Luger1995ComparisonOC,
  title={Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans},
  author={Steven W. Luger and Philip W. Paparone and Gary P. Wormser and Robert B. Nadelman and Edgar Grunwaldt and Gema Gomez and M Wisniewski and Jeffrey J. Collins},
  journal={Antimicrobial Agents and Chemotherapy},
  year={1995},
  volume={39},
  pages={661 - 667}
}
A randomized, multicenter, investigator-blinded clinical trial was undertaken in order to compare the efficacies of cefuroxime axetil and doxycycline in the treatment of patients with Lyme disease associated with erythema migrans. A total of 232 patients with physician-documented erythema migrans were treated orally for 20 days with either cefuroxime axetil, 500 mg twice daily (119 patients), or doxycycline, 100 mg three times daily (113 patients), and clinical evaluations were conducted during… Expand
Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease.
TLDR
The number of patients in this trial was not sufficient to demonstrate a statistically significant difference between the 3 groups; however, both amoxicillin and cefuroxime axetil seem to be safe, efficacious treatments for children with early LD. Expand
Treatment of erythema migrans with doxycycline for 10 days versus 15 days.
TLDR
The 10-day regimen of oral doxycycline was not inferior to the 15- day regimen among adult European patients with solitary erythema migrans and the frequency of nonspecific symptoms after treatment was similar to that among control subjects. Expand
Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial
TLDR
The 14 day oral doxycycline was not inferior to the 14’day intravenous ceftriaxone in treatment of adult European patients with early disseminated Lyme borreliosis manifested as multiple EM, and the frequency of non-specific symptoms in patients was similar to that in controls. Expand
Duration of Antibiotic Therapy for Early Lyme Disease
TLDR
Oral doxycycline alone for 10 days is sufficient treatment for patients with early Lyme disease that manifests as erythema migrans, and the outcome of therapy might be enhanced by treatment with a parenteral agent such as ceftriaxone, which readily crosses the bloodbrain barrier. Expand
Subjective symptoms after treatment of early Lyme disease.
TLDR
Doxycycline and cefuroxime axetil had comparable efficacy in the treatment of European patients with erythema migrans and the frequency of nonspecific symptoms in patients did not exceed that of a control group at > or =6 months after enrollment. Expand
Cefuroxime Axetil
TLDR
Cefuroxime axetil is a broad spectrum antibacterial agent with a pharmacokinetic profile that permits convenient twice-daily administration and is an effective and well tolerated treatment in patients with various infections, including otitis media, pharyngitis, sinusitis, CAP and acute exacerbations of chronic bronchitis. Expand
Is the risk of early neurologic Lyme borreliosis reduced by preferentially treating patients with erythema migrans with doxycycline?
TLDR
Available data suggest that oral doxycycline is not superior to comparators for preventing NLB in patients receiving treatment for erythema migrans, and patients receiving nondoxycycline treatment regimens collectively might have at most a 0.5% greater risk for developing NLB. Expand
Doxycycline-induced photosensitivity in patients treated for erythema migrans
TLDR
Photosensitivity reactions in adult patients with EM treated with doxycycline 100 mg twice daily for 10–15 days occurred rarely, were not severe, and had no long-term sequelae. Expand
Comparison of a Two- or Three-Week Regimen and a Review of Treatment of Erythema Migrans with Phenoxymethylpenicillin
TLDR
A 2-week treatment regimen of PenV seems to be as effective as a 3-week course with no statistical differences for clinical and serological findings after treatment. Expand
Review of Treatment Options for Lyme Borreliosis
TLDR
The parenteral agent ceftriaxone is the drug of choice for severe acute and chronic infections, due to good penetration into CSF, convenient single daily dosage regimen and proven high efficacy in clinical trials involving a wide variety of disseminated infections. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease.
TLDR
Cefuroxime axetil is well tolerated and appears to be equally as effective as doxycycline in the treating of early Lyme disease and in preventing the subsequent development of late Lyme disease. Expand
Antibiotic therapy in Lyme disease.
TLDR
It is concluded that penicillin therapy shortens the duration of erythema chronicum migrans and may prevent or attenuate subsequent arthritis. Expand
Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis
TLDR
The two regimens were equally effective for treatment of erythema migrans and none of the patients needed further antibiotic treatment for Lyme borreliosis. Expand
Treatment of the early manifestations of Lyme disease.
TLDR
For patients with early Lyme disease, tetracycline appears to be the most effective drug, then penicillin, and finally erythromycin; with all three antibiotic agents nearly half of the patients had minor late symptoms such as headache, musculoskeletal pain, and lethargy. Expand
Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents
TLDR
Results indicate that the in vitro and in vivo activities of cefuroxime against B. burgdorferi are comparable to those of several oral antibiotics currently being used in the treatment of early Lyme disease and suggest that the oral form of this cephalosporin may be an effective alternative therapy for this disease. Expand
The spirochetal etiology of Lyme disease.
TLDR
It is concluded that the I. dammini spirochete is the causative agent of Lyme disease and nymphal or adult lxodes dammini ticks in Connecticut. Expand
ASSOCIATION OF CHRONIC LYME ARTHRITIS WITH HLA‐DR4 and HLA‐DR2 ALLELES
TLDR
Particular Class II major histocompatibility genes determine a host immune response to B. burgdorferi that results in chronic arthritis and lack of response to antibiotics, and appear to act as independent, dominant markers of susceptibility. Expand
Effect of dose and food on the bioavailability of cefuroxime axetil.
TLDR
There was a linear relationship between the fed dose and both the area under the plasma concentration time curve and the peak plasma concentration and a comparison of the AUC for the oral and intravenous data revealed that absorption is an apparent zero order process from 0.5 to 3 h after dosing. Expand
In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone
TLDR
In vitro susceptibilities of eight Borrelia burgdorferi isolates to five oral cephalosporins were determined and at least 72 h of incubation was required to kill 99% of the organisms. Expand
Geographical and temporal distribution of babesial infection in Connecticut
TLDR
There is a considerable risk of babesial infection among residents of the Connecticut mainland who are seropositive for Lyme disease, a risk that appears to have remained constant over the past 5 years. Expand
...
1
2
...